3 antibody; and anti glypican 3 antibody that has a plasma half life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti glypican 3 antibody, and a method of preparing {HEAD ~ the anti glypican 3 antibody} and producing a pharmaceutical composition comprising {TAIL ~ the anti glypican 3 antibody} as an active ingredient 
3 antibody ; and anti glypican 3 antibody that has a plasma half life that has been modulated by amino acid residue modification , a pharmaceutical composition comprising as an active ingredient the anti glypican 3 antibody , and a method of preparing { HEAD ~ the anti glypican 3 antibody } and producing a pharmaceutical composition comprising { TAIL ~ the anti glypican 3 antibody } as an active ingredient
OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH HEAD HEAD HEAD HEAD HEAD HEAD HEAD HEAD HEAD OTH OTH OTH OTH OTH OTH TAIL TAIL TAIL TAIL TAIL TAIL TAIL TAIL TAIL OTH OTH OTH OTH